Humanin — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Humanin

Also known as: HN, MTRNR2, MT-RNR2, Rattin (rat homolog), HNG (S14G-humanin analog), [Gly14]-Humanin, Humanin G, HNG17, Colivelin (fusion derivative)

Mitochondria-derived peptide (MDP); 24-amino acid endogenous micropeptide encoded by a short open reading frame within the 16S ribosomal RNA gene (MT-RNR2) of m

Research chemicalLast updated: October 31, 2026Based on 40 peer-reviewed studies

What it is

Humanin is a small peptide the body makes naturally, mostly in brain and nerve cells. Researchers are studying it as a possible protector of brain and heart cells, and as a biomarker for Alzheimer's, diabetes, and age-related decline. No FDA-approved use yet; the research is still at an early stage.

The scientific side

Humanin (HN) is a 24-amino acid endogenous peptide encoded by a short open reading frame within the mitochondrial 16S rRNA gene (MT-RNR2) (PMID 26667157, PMID 39950467). It was first identified in brain tissue of an Alzheimer's disease (AD) patient as a factor antagonizing neuronal cell death induced by AD-associated insults. HN exerts cytoprotective, anti-apoptotic, anti-oxidant, and anti-inflammatory effects through multiple intracellular and extracellular mechanisms. Extracellularly, HN binds to a heterotrimeric cell-surface receptor (htHNR) composed of CNTFRα, WSX-1, and gp130, activating the JAK2/STAT3 pro-survival signaling pathway (PMID 19997871, PMID 21335658, PMID 16958985). Intracellularly, HN interacts with pro-apoptotic proteins such as BAX and IGFBP-3, preventing activation of apoptotic cascades. HN inhibits BAX-driven mitochondrial oxidative stress. HN activates AMPK, leading to phosphorylation of ULK1 and Beclin1, promoting mitophagy and clearance of damaged mitochondria. HN also inhibits Z-DNA/ZBP1-mediated necroptosis, promotes resolution of inflammation via efferocytic macrophages, and upregulates autophagy pathways promoting cell survival under metabolic stress. HN reduces weight gain, visceral fat, and increases glucose-stimulated insulin release. HN binds amyloid beta (Aβ), blocking Aβ aggregation enhanced by acetylcholinesterase. Its potent analog S14G-humanin (HNG) is reported to be approximately 1000-fold more potent than native HN. HN levels decline with aging but may increase compensatorily in some disease states (PMID 40090538, PMID 36642986).

Class: Mitochondria-derived peptide (MDP); 24-amino acid endogenous micropeptide encoded by a short open reading frame within the 16S ribosomal RNA gene (MT-RNR2) of mitochondrial DNA

Administration & storage

Administration
Intraperitoneal injection — HNG in rodent studies (PMID: 37814907PMID: 38163419PMID: 38054825PMID: 40639309PMID: 39435863)Subretinal injection — FITC-labeled Aβ model in vivo (PMID: 42333946)Intratracheal instillation — LPS for ALI model (not HNG itself) (PMID: 38054825)
Storage
No storage conditions for humanin or its analogs are described in any of the reviewed abstracts.
Cautions
HN has been shown to act as a pro-tumoral factor in glioblastoma, activating the ITGAV-TGFβ signaling axis and worsening survival outcomes in an orthotopic mouse model — potential oncogenic risk warrants caution.,A curvilinear (U-shaped) association between circulating humanin levels and cardiovascular mortality/morbidity has been observed in hemodialysis patients, suggesting that both very low and very high humanin levels may be harmful (PMID: 39102184, PMID: 41849628).,Humanin variants form amyloid-like β-sheet fibrils; the implications of fibrillization for administered peptide are not fully characterized.,All dosing data in the reviewed literature is from preclinical (animal) models; no human pharmacokinetic or safety data from clinical trials of exogenously administered humanin or analogs are present in the reviewed abstracts.,Sterile technique is essential when preparing any injectable peptide to prevent contamination and infection.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification